T2D.com vs Wisp
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
T2D.com
Best for diabetic GLP-1 accessStarting at $999/mo
Wisp
Best for buyers who want a board-certified telehealth platform offering both branded injectables AND a sublingual alternative — with full disclosure that the sublingual form is not human-testedStarting at $225/mo
Side-by-Side Comparison
| Feature | T2D.com | Wisp |
|---|---|---|
| Overall Score | 6.1/10 | ✓7.0/10 |
| Starting Price | $999/mo | ✓$225/mo |
| Editorial Rating | 3.1 ★ /5 | ✓3.5 ★ /5 |
| Features | ✓7 features | 6 features |
| States Available | ✓1 | 0 |
| Compounded | ✓ Yes | ✓ Yes |
| Brand Name | — | — |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
Pros & Cons
T2D.com
Pros
- ✓Built specifically for type 2 diabetic and pre-diabetic patients
- ✓Integrated service — prescriber, pharmacy, and delivery handled in one flow
- ✓Offers both compounded semaglutide and compounded tirzepatide
- ✓Temperature-controlled home delivery via UPS or FedEx
- ✓Ongoing prescriber monitoring and support included
Cons
- ✗No pricing published on the public website — must register to see costs
- ✗No states list published on the site
- ✗Newer brand with limited independent reviews
- ✗Compounded only — no brand-name Ozempic, Wegovy, or Mounjaro
Wisp
Pros
- ✓Wider GLP-1 menu than the prior stub suggested — both branded injectables (Wegovy, Zepbound, Saxenda) AND the compounded sublingual option
- ✓LegitScript certified, board-certified providers (Dr. Shannon Chatham DO, Andrea Sleeth WHNP-BC publicly named)
- ✓Wisp's product page uses appropriately cautious language around sublingual: 'lab tests using human-derived tissues suggest it may begin working' and 'effectiveness in patients may vary' — disclosure is more rigorous than most compounded GLP-1 marketing
Cons
- ✗EFFECTIVENESS CAVEAT: sublingual compounded semaglutide has not been tested in humans — Wisp's own product page explicitly states this. Injectables (Wegovy, Zepbound, Saxenda) on the same platform have FDA safety/efficacy data; sublingual does not.
- ✗Pharmacy partners not publicly named
- ✗States served list not publicly enumerated
Our Verdict
Wisp edges out T2D.com with a higher overall score of 7.0/10 and is particularly strong for buyers who want a board-certified telehealth platform offering both branded injectables AND a sublingual alternative — with full disclosure that the sublingual form is not human-tested. T2D.com remains a solid alternative, especially if you're looking for diabetic GLP-1 access.
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.